A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance
Top Cited Papers
- 31 March 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 73 (4), 891-899
- https://doi.org/10.1093/jac/dkx480
Abstract
Background: Candida auris has emerged globally as an MDR nosocomial pathogen in ICU patients. Objectives: We studied the antifungal susceptibility of C. auris isolates (n = 350) from 10 hospitals in India collected over a period of 8 years. To investigate azole resistance, ERG11 gene sequencing and expression profiling was conducted. In addition, echinocandin resistance linked to mutations in the C. auris FKS1 gene was analysed. Methods: CLSI antifungal susceptibility testing of six azoles, amphotericin B, three echinocandins, terbinafine, 5-flucytosine and nystatin was conducted. Screening for amino acid substitutions in ERG11 and FKS1 was performed. Results: Overall, 90% of C. auris were fluconazole resistant (MICs 32 to >= 64 mg/L) and 2% and 8% were resistant to echinocandins (>= 8 mg/L) and amphotericin B (>= 2 mg/L), respectively. ERG11 sequences of C. auris exhibited amino acid substitutions Y132 and K143 in 77% (n = 34/44) of strains that were fluconazole resistant whereas WT genotypes, i.e. without substitutions at these positions, were observed in isolates with low fluconazole MICs (1-2 mg/L) suggesting that these substitutions confer a phenotype of resistance to fluconazole similar to that described for Candida albicans. No significant expression of ERG11 was observed, although expression was inducible in vitro with fluconazole exposure. Echinocandin resistance was linked to a novel mutation S639F in FKS1 hot spot region I. Conclusions: Overall, 25% and 13% of isolates were MDR and multi-azole resistant, respectively. The most common resistance combination was azoles and 5-flucytosine in 14% followed by azoles and amphotericin B in 7% and azoles and echinocandins in 2% of isolates.Funding Information
- Indian Council of Medical Research (5/3/3/26/2010-ECD-I)
This publication has 44 references indexed in Scilit:
- New Clonal Strain ofCandida auris, Delhi, IndiaEmerging Infectious Diseases, 2013
- First Three Reported Cases of Nosocomial Fungemia Caused by Candida aurisJournal of Clinical Microbiology, 2011
- Validation of 24-Hour Posaconazole and Voriconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Application of Epidemiological Cutoff Values to Results from a Global Candida Antifungal Surveillance ProgramJournal of Clinical Microbiology, 2011
- Investigation of mutations in Erg11 gene of fluconazole resistant Candida albicans isolates from Turkish hospitalsMycoses, 2011
- Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literatureDiagnostic Microbiology and Infectious Disease, 2010
- Candida haemuloniiand Closely Related Species at 5 University Hospitals in Korea: Identification, Antifungal Susceptibility, and Clinical FeaturesClinical Infectious Diseases, 2009
- Candida aurissp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospitalMicrobiology and Immunology, 2009
- SertaconazoleDrugs, 2009
- Validation of 24-Hour Fluconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Results from a Global Candida Antifungal Surveillance ProgramJournal of Clinical Microbiology, 2008
- Resistance Mechanisms in Clinical Isolates of Candida albicansAntimicrobial Agents and Chemotherapy, 2002